Related Experiment Video
Updated: May 7, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
Osteonecrosis of the jaw related to everolimus: a case report
Dong Wook Kim1, Young-Soo Jung, Hyung-Sik Park
1Department of Oral & Maxillofacial Surgery, Oral Science Research Center, Yonsei University College of Dentistry, Seoul, Republic of Korea.
Abstract:
Antiresorptive agent-related osteonecrosis of the jaw results in appreciable morbidity in affected patients. Nowadays many physicians prescribe an antiangiogenic agent for the management of malignant metastases. Everolimus is a serine-threonine kinase that acts as an inhibitor of mammalian target of rapamycin, which results in reduced growth of cells, angiogenesis, and survival of cells. We report the first case to our knowledge of osteonecrosis of the jaw that seemed to result from the additive effect of everolimus.
Insights
Osteonecrosis of the jaw (ONJ) can cause significant patient morbidity. This case suggests that the drug everolimus, an antiangiogenic agent, may contribute to ONJ, potentially due to additive effects with other medications.
Area of Science:
- Oncology
- Pharmacology
- Oral Surgery
Background:
- Antiresorptive agents are known to cause osteonecrosis of the jaw (ONJ).
- Antiangiogenic agents, such as everolimus, are increasingly used for managing malignant metastases.
- Everolimus inhibits mammalian target of rapamycin (mTOR), affecting cell growth, angiogenesis, and survival.
Observation:
- A patient developed osteonecrosis of the jaw.
Findings:
- This case is the first to suggest a potential link between everolimus and ONJ.
- The osteonecrosis may result from the additive effect of everolimus, possibly in combination with other therapies.
Implications:
- Clinicians should be aware of the potential risk of ONJ when prescribing everolimus, especially in patients receiving antiresorptive agents.
- Further research is needed to elucidate the exact mechanism and incidence of everolimus-induced ONJ.
Related Concept Videos
Osteoclasts in Bone Remodeling
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Bone Remodeling
